Industry Insights

1. Avoiding Extraction And Chemical Characterization Pitfalls In Complex Medical Devices 11/2/2026

   Tissue-derived materials, hydrogels, absorbables, silicones, and drug-containing components can behave unpredictably under extraction. Study designs that ignore this produce data that is technically accurate yet clinically misleading.

2. Advance Fluidic And Optical Systems With The Right Partnership 10/28/2026

   Juggling separate fluidics and optics suppliers slows development. See how one engineering partner can streamline integration, improve accuracy, and speed scale-up.

3. Why Instrument Developers Trust IDEX Health & Science For OEM, Fluidics, And Optics Systems 10/28/2026

   Explore how OEMs optimize instrument performance with precision fluidics, optical technologies, and integrated subsystems that improve reliability and accelerate development.

4. Edge Filters vs. Notch Filters For Raman Instrumentation 10/28/2026

   Edge or notch filter? Learn how each blocks the laser line in Raman systems and which delivers the low-shift reach, tunability, or Stokes/anti-Stokes coverage your application needs.

5. The PMCF Decision Guide 10/14/2026

   Proposed EU reforms may remove standalone PMCF reporting, yet the duty to proactively collect clinical data remains. Method selection, notified body defense, and data-capture cost determine what comes next.

6. Accelerating Enrollment For Direct-To-Patient Observational Studies 10/14/2026

   Removing the handoff between patient self-screening and enrollment changes what a fully virtual observational study can achieve, from conversion at peak intent to completion rates among participants.

7. Getting Ahead Of PFAS Risk In Pharmaceutical Manufacturing 10/14/2026

   Pharma can’t simply eliminate essential PFAS uses. A phased, risk-based strategy can address footprint, exposure, and supply risks amid regulatory uncertainty.

8. PFAS In Medical Devices: What's New And What To Do 10/14/2026

   Regulators now separate fluoropolymers from other PFAS, but lifecycle risks remain. Readiness starts with knowing which uses, reporting duties, and exposures matter most.

9. A Risk Management Approach For The Pharmaceutical Industry 10/14/2026

   Replacing fluorinated chemistries across pharma isn’t simple. Growing pressures make it critical to prioritize risks and take a sequenced, evidence-based approach to mitigation.

10. Your Quality Team Is Already Using AI To Draft Compliance Documents 10/8/2026

    Quality teams already use general-purpose AI for deviations and submission drafts without validation. Regulators expect governance, and the gap is an undocumented process step, not unreliable output.